Filament Health (FH.NEO) got the nod from the Financial Regulatory Authority to start trading on the OTC Pink Market in the United States under the symbol “FLHLF,” and has also submitted an application to get on the OTCQB Venture Market, according to a press release.


Actually, Filament isn’t stopping there. Their latest bid for greater exposure includes applications for the Depository Trust Company (DTC) to get eligibility to list there as well. Doing this simplifies the process of trading the company’s shares.


“We are pleased to have initiated our listing process on the OTCQB. This listing will enhance our visibility and allow Filament’s common shares
to be more available to a broad range of institutional and retail investors in the United States,” said Benjamin Lightburn, CEO of Filament.


If you’re not familiar, Filament is a Vancouver-based natural psychedelics drug discovery and extraction tech company, engaged in natural extractions and commercialization, using its intellectual property portfolio, good manufacturing practices certified facility, and Health Canada dealer’s license for all natural psychedelics.

What are the OTC markets

The OTC Markets Group operates the OTCQX Best Market, the OTCQB Venture Market and the Pink Open Market, giving investors access to 11,000 United States and global securities. The OTC Link ATS, OTC Link ECN, offers connections to a network of broker-dealers providing liquidity and execution services.


The listing of the company’s shares on the OTCQB still needs to get the nod from the OTCQB board itself after satisfying the applicable listing requirements. The company will provide updates when they’re available.



Filament Health is down $0.055 and presently trading at $0.33.

—Joseph Morton

Full disclosure: Filament Health is an marketing client.

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
Depository Trust Company
Filament Health
OTC markets
OTCQX Best Market
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments